Last reviewed · How we verify
NGM120
At a glance
| Generic name | NGM120 |
|---|---|
| Sponsor | NGM Biopharmaceuticals, Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Gamma-glutamyltransferase increased
- Anaemia
- Insomnia
- Constipation
- Diarrhoea
- Nausea
- Oedema peripheral
- Blood alkaline phosphatase increased
- Weight decreased
- Dizziness
- Hyponatraemia
Key clinical trials
- An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. (PHASE2)
- Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy (PHASE1, PHASE2)
- Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NGM120 CI brief — competitive landscape report
- NGM120 updates RSS · CI watch RSS
- NGM Biopharmaceuticals, Inc portfolio CI